476 related articles for article (PubMed ID: 28854169)
1. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease.
Mass E; Jacome-Galarza CE; Blank T; Lazarov T; Durham BH; Ozkaya N; Pastore A; Schwabenland M; Chung YR; Rosenblum MK; Prinz M; Abdel-Wahab O; Geissmann F
Nature; 2017 Sep; 549(7672):389-393. PubMed ID: 28854169
[TBL] [Abstract][Full Text] [Related]
2. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
3. EMPhasis on Mutant Microglia: Dysregulation of Brain Sentinels Induces Neurodegeneration.
Schreiner B; Greter M
Cell Stem Cell; 2017 Nov; 21(5):566-568. PubMed ID: 29100009
[TBL] [Abstract][Full Text] [Related]
4. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H
Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638
[TBL] [Abstract][Full Text] [Related]
5. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
6. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of MEK inhibition in patients with histiocytic neoplasms.
Diamond EL; Durham BH; Ulaner GA; Drill E; Buthorn J; Ki M; Bitner L; Cho H; Young RJ; Francis JH; Rampal R; Lacouture M; Brody LA; Ozkaya N; Dogan A; Rosen N; Iasonos A; Abdel-Wahab O; Hyman DM
Nature; 2019 Mar; 567(7749):521-524. PubMed ID: 30867592
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
9. Erythro-myeloid progenitors can differentiate from endothelial cells and modulate embryonic vascular remodeling.
Kasaai B; Caolo V; Peacock HM; Lehoux S; Gomez-Perdiguero E; Luttun A; Jones EA
Sci Rep; 2017 Mar; 7():43817. PubMed ID: 28272478
[TBL] [Abstract][Full Text] [Related]
10. Cellular model of neuronal atrophy induced by DYNC1I1 deficiency reveals protective roles of RAS-RAF-MEK signaling.
Liu ZD; Zhang S; Hao JJ; Xie TR; Kang JS
Protein Cell; 2016 Sep; 7(9):638-50. PubMed ID: 27510948
[TBL] [Abstract][Full Text] [Related]
11. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
12. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow-derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis.
Xiao Y; van Halteren AGS; Lei X; Borst J; Steenwijk E; de Wit T; Grabowska J; Voogd R; Kemps P; Picarsic J; van den Bos C; Borst J
Blood; 2020 Nov; 136(19):2188-2199. PubMed ID: 32750121
[TBL] [Abstract][Full Text] [Related]
14. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
15. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
[TBL] [Abstract][Full Text] [Related]
16. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.
Eisenhardt AE; Olbrich H; Röring M; Janzarik W; Anh TN; Cin H; Remke M; Witt H; Korshunov A; Pfister SM; Omran H; Brummer T
Int J Cancer; 2011 Nov; 129(9):2297-303. PubMed ID: 21190184
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
19. BRAF somatic mutations in malignant melanoma and melanocytic naevi.
Thomas NE
Melanoma Res; 2006 Apr; 16(2):97-103. PubMed ID: 16567964
[TBL] [Abstract][Full Text] [Related]
20. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]